Tissue Array
Log In | My Account | Cart (0 items) - $0.00
US Biomax, Inc.
 

BR10010

Breast cancer and matched metastatic carcinoma tissue array, including TNM and pathology grade, with ER, PR and Her-2 (neu) IHC results, 50 cases/100 cores, replaced by BR10010a
H&E (BR10010s*): $255.00 Add to Cart

Microarray Panel:Breast carcinoma and matched metastatic carcinoma tissue microarray, containing 50 cases of breast carcinoma (46 invasive ductal carcinoma, 1 micropapillary carcinoma, 2 invasive lobular carcinoma, 1 neuroendocrine carcinoma), 50 matched metastatic carcinoma, duplicate cores per case
Cores:100
Cases:50
Layout:10 cols × 10 rows
Core Diameter:1 mm
Thickness:5 µm
Quality Control:Anti-Actin confirmed
Applications:Routine histology procedures including ImmunoHistochemistry (IHC) and In Situ Hybridization (ISH), protocols which can be found on our support page.
Notes:Unless specified, all TMA slides are not coated with extra layer of paraffin (tissue cores can be easily seen on the glass), so there is no need to bake, can be directly put into xylene for de-paraffin procedure.

*Tissue Microarray Slide Types:

  • Unstained: unstained paraffin tissue microarray slide.
  • Trial: tissue microarray trial slide. 10% - 25% of cores missing. Good for titrating antibody dilution and experiment conditions. Limited numbers are available, to 2 per item per order. Test slides (tissue arrays with catalog numbers ending with 241 or 242) are recommended as a substitute.
  • H & E: Hematoxylin and Eosin stained tissue microarray slide.

Microarray Panel Display

 
Slide Label: US Biomax, Inc. Tissue Array
12345678910 
A Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre  
B Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre  
C Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre  
D Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre  
E Bre Bre Bre Bre Bre Bre Bre Bre Bre Bre  
F Lym Lym Lym Lym Lym Lym Lym Lym Lym Lym  
G Lym Lym Lym Lym Lym Lym Lym Lym Lym Lym  
H Lym Lym Lym Lym Lym Lym Lym Lym Lym Lym  
I Lym Lym Lym Lym Lym Lym Lym Lym Lym Lym  
J Lym Lym Lym Lym Lym Lym Lym Lym Lym Lym Marked point
Legend: Bre - Breast, Lym - Lymph node

- Malignant tumor, - Malignant tumor (stage IIIa), - Malignant tumor (stage IIIb), - Malignant tumor (stage IIa), - Malignant tumor (stage IIb), - Metastasis

Specification Sheet

Pos No. Sex Age Organ Pathology diagnosis Grade Stage TNM ER PR HER2 Type †
A1 1 F 59 Breast Invasive ductal carcinoma 1 IIIa T2N2M0 – – +++, 100% Malignant
A2 2 F 80 Breast Invasive ductal carcinoma 1 IIIa T2N2M0 +, 9% – +++, 100% Malignant
A3 3 F 66 Breast Invasive ductal carcinoma 1 IIa T1N1M0 +, 10% – +++, 100% Malignant
A4 4 F 44 Breast Invasive ductal carcinoma 1 IIIa T2N2M0 ++, 95% +, 25% – Malignant
A5 5 F 28 Breast Invasive ductal carcinoma 1 IIIa T3N2M0 1% – +++, 100% Malignant
A6 6 F 39 Breast Invasive ductal carcinoma 2 IIb T3N1M0 – – +, 90% Malignant
A7 7 F 42 Breast Invasive ductal carcinoma (sparse) – IIb T2N1M0 – – +++, 99% Malignant
A8 8 F 28 Breast Invasive ductal carcinoma 2 IIa T1N1M0 – +, 1% +++, 100% Malignant
A9 9 F 52 Breast Invasive ductal carcinoma 2 IIIa T2N2M0 +, 25% – ++, 90% Malignant
A10 10 F 55 Breast Invasive ductal carcinoma 2 IIb T2N1M0 – – – Malignant
B1 11 F 58 Breast Invasive ductal carcinoma 2 IIb T2N1M0 +++, 100% +++, 98% +, 95% Malignant
B2 12 F 56 Breast Invasive ductal carcinoma 2 IIb T2N1M0 +, 50% – – Malignant
B3 13 F 53 Breast Invasive ductal carcinoma 2 IIa T1N1M0 – – +++, 100% Malignant
B4 14 F 51 Breast Invasive ductal carcinoma 2 IIIb T4N2M0 +, 20% +++, 95% +, 80% Malignant
B5 15 F 40 Breast Invasive ductal carcinoma 2 IIIa T2N2M0 – – +++, 100% Malignant
B6 16 F 42 Breast Invasive ductal carcinoma 2 IIb T2N1M0 – – +++, 100% Malignant
B7 17 F 41 Breast Invasive ductal carcinoma 2 IIIa T2N2M0 +, 80% ++, 95% ++, 90% Malignant
B8 18 F 28 Breast Invasive ductal carcinoma 2 IIIa T2N2M0 +, 50% ++, 45% ++, 99% Malignant
B9 19 F 60 Breast Invasive ductal carcinoma 2 IIb T2N1M0 ++, 90% +++, 99% ++, 95% Malignant
B10 20 F 70 Breast Invasive ductal carcinoma 2 IIb T2N1M0 – – +++, 100% Malignant
C1 21 F 52 Breast Invasive ductal carcinoma 2 IIb T2N1M0 +, 15% – +++, 90% Malignant
C2 22 F 59 Breast Invasive ductal carcinoma 2 IIb T2N1M0 +, 3% – ++, 60% Malignant
C3 23 F 53 Breast Invasive ductal carcinoma 1 IIb T2N1M0 – – +++, 100% Malignant
C4 24 F 48 Breast Invasive ductal carcinoma 2 IIb T2N1M0 – +, 5% – Malignant
C5 25 F 58 Breast Invasive ductal carcinoma 2 IIIa T2N2M0 – – – Malignant
C6 26 F 46 Breast Invasive ductal carcinoma 2 IIIa T3N2M0 – – ++, 95% Malignant
C7 27 F 42 Breast Invasive ductal carcinoma 2 IIIa T2N2M0 – +, 90% ++, 98% Malignant
C8 28 F 55 Breast Invasive ductal carcinoma 2 IIb T2N1M0 +, 45% ++, 95% – Malignant
C9 29 F 40 Breast Invasive ductal carcinoma 2 IIb T2N1M0 – – – Malignant
C10 30 F 48 Breast Invasive ductal carcinoma 2 IIb T3N1M0 – – – Malignant
D1 31 F 31 Breast Invasive ductal carcinoma 2 IIb T3N1M0 +, 25% +, 5% ++, 100% Malignant
D2 32 F 56 Breast Invasive ductal carcinoma 2 IIb T2N1M0 – – +, 50% Malignant
D3 33 F 75 Breast Invasive ductal carcinoma 3 IIb T3N1M0 +, 90% – +, 95% Malignant
D4 34 F 62 Breast Invasive ductal carcinoma 2 IIb T2N1M0 – – ++, 100% Malignant
D5 35 F 50 Breast Invasive ductal carcinoma 2 IIb T3N1M0 – +, 5% – Malignant
D6 36 F 53 Breast Invasive ductal carcinoma 2 IIb T2N1M0 +++, 99% ++, 5% ++, 100% Malignant
D7 37 F 49 Breast Invasive ductal carcinoma 2 IIIa T3N2M0 – – +, 40% Malignant
D8 38 F 47 Breast Invasive ductal carcinoma 2 IIb T2N1M0 – – +, 30% Malignant
D9 39 F 39 Breast Invasive ductal carcinoma 2 IIb T2N1M0 +, 8% +++, 98% +, 40% Malignant
D10 40 F 57 Breast Invasive ductal carcinoma 2 IIIa T2N2M0 – – +++, 100% Malignant
E1 41 F 49 Breast Invasive ductal carcinoma 2 IIb T3N1M0 +, 22% – +++, 100% Malignant
E2 42 F 42 Breast Invasive ductal carcinoma 2 IIIa T2N2M0 ++, 50% +++, 80% – Malignant
E3 43 F 48 Breast Invasive ductal carcinoma 3 IIb T3N1M0 – – – Malignant
E4 44 F 53 Breast Invasive ductal carcinoma 3 IIIb T4N2M0 +, 6% – +, 60% Malignant
E5 45 F 33 Breast Invasive ductal carcinoma 3 IIb T2N1M0 – – +, 95% Malignant
E6 46 F 72 Breast Invasive ductal carcinoma 3 IIb T2N1M0 – – +, 20% Malignant
E7 47 F 49 Breast Micropapillary carcinoma – IIb T2N1M0 – – +++, 100% Malignant
E8 48 F 78 Breast Invasive lobular carcinoma – IIb T2N1M0 – – – Malignant
E9 49 F 39 Breast Invasive lobular carcinoma – IIb T2N1M0 – – – Malignant
E10 50 F 45 Breast Neuroendocrine carcinoma – IIb T2N1M0 +++, 75% – 0.9 Malignant
F1 51 F 59 Lymph node Metastatic carcinoma (fibrofatty tissue and blood vessel) from breast – – – +, 20% – +++, 100% Metastasis
F2 52 F 80 Lymph node Metastatic carcinoma from breast – – – +, 1% – +++, 100% Metastasis
F3 53 F 66 Lymph node Metastatic carcinoma from breast – – – – – +++, 100% Metastasis
F4 54 F 44 Lymph node Metastatic carcinoma from breast – – – +++, 100% +++, 99% – Metastasis
F5 55 F 28 Lymph node Metastatic carcinoma from breast – – – +, 10% – +++, 100% Metastasis
F6 56 F 39 Lymph node Metastatic carcinoma from breast – – – – – +, 80% Metastasis
F7 57 F 42 Lymph node Metastatic carcinoma (sparse) from breast – – – +, 15% – +++, 100% Metastasis
F8 58 F 28 Lymph node Metastatic carcinoma from breast – – – ++, 40% – +++, 90% Metastasis
F9 59 F 52 Lymph node Metastatic carcinoma from breast – – – ++, 90% – ++, 85% Metastasis
F10 60 F 55 Lymph node Metastatic carcinoma from breast – – – – – – Metastasis
G1 61 F 58 Lymph node Metastatic carcinoma from breast – – – ++, 100% +++, 99% +, 85% Metastasis
G2 62 F 56 Lymph node Metastatic carcinoma from breast – – – +++, 70% +++, 99% +, 99% Metastasis
G3 63 F 53 Lymph node Metastatic carcinoma from breast – – – – – +++, 100% Metastasis
G4 64 F 51 Lymph node Metastatic carcinoma from breast – – – +++, 99% +++, 98% ++, 100% Metastasis
G5 65 F 40 Lymph node Metastatic carcinoma from breast – – – – +, 20% +++, 100% Metastasis
G6 66 F 42 Lymph node Metastatic carcinoma from breast – – – – – – Metastasis
G7 67 F 41 Lymph node Metastatic carcinoma from breast – – – +, 3% +, 25% +, 99% Metastasis
G8 68 F 28 Lymph node Metastatic carcinoma (sparse) from breast – – – +, 25% ++, 95% +, 89% Metastasis
G9 69 F 60 Lymph node Metastatic carcinoma from breast – – – +++, 98% +++, 99% +, 90% Metastasis
G10 70 F 70 Lymph node Metastatic carcinoma from breast – – – – – +++, 100% Metastasis
H1 71 F 52 Lymph node Metastatic carcinoma from breast – – – +, 35% – +++, 100% Metastasis
H2 72 F 59 Lymph node Metastatic carcinoma from breast – – – +, 15% +++, 50% +, 90% Metastasis
H3 73 F 53 Lymph node Metastatic carcinoma from breast – – – – – +++, 100% Metastasis
H4 74 F 48 Lymph node Metastatic carcinoma from breast – – – – +, 45% – Metastasis
H5 75 F 58 Lymph node Metastatic carcinoma from breast – – – +, 10% – – Metastasis
H6 76 F 46 Lymph node Metastatic carcinoma from breast – – – +, 6% – ++, 99% Metastasis
H7 77 F 42 Lymph node Metastatic carcinoma from breast – – – +, 4% ++, 98% +++, 100% Metastasis
H8 78 F 55 Lymph node Metastatic carcinoma from breast – – – +, 5% +++, 95% – Metastasis
H9 79 F 40 Lymph node Metastatic carcinoma from breast – – – – – +++, 100% Metastasis
H10 80 F 48 Lymph node Metastatic carcinoma from breast – – – – – +++, 100% Metastasis
I1 81 F 31 Lymph node Metastatic carcinoma from breast – – – ++, 99% – +++, 100% Metastasis
I2 82 F 56 Lymph node Metastatic carcinoma from breast – – – – – +, 90% Metastasis
I3 83 F 75 Lymph node Metastatic carcinoma from breast – – – – +, 1% – Metastasis
I4 84 F 62 Lymph node Metastatic carcinoma from breast – – – – – +, 90% Metastasis
I5 85 F 50 Lymph node Metastatic carcinoma from breast – – – +++, 50% +, 15% +, 15% Metastasis
I6 86 F 53 Lymph node Metastatic carcinoma from breast – – – +++, 20% +, 2% +++, 100% Metastasis
I7 87 F 49 Lymph node Metastatic carcinoma from breast – – – – – +, 40% Metastasis
I8 88 F 47 Lymph node Metastatic carcinoma from breast – – – – – – Metastasis
I9 89 F 39 Lymph node Metastatic carcinoma from breast – – – – +, 4% – Metastasis
I10 90 F 57 Lymph node Metastatic carcinoma from breast – – – – – +++, 100% Metastasis
J1 91 F 49 Lymph node Metastatic carcinoma from breast – – – ++, 75% – +++, 100% Metastasis
J2 92 F 42 Lymph node Metastatic carcinoma from breast – – – – +, 1% – Metastasis
J3 93 F 48 Lymph node Metastatic carcinoma from breast – – – – – – Metastasis
J4 94 F 53 Lymph node Metastatic carcinoma from breast – – – – – +, 85% Metastasis
J5 95 F 33 Lymph node Metastatic carcinoma from breast – – – – – – Metastasis
J6 96 F 72 Lymph node Metastatic carcinoma from breast – – – – +++, 80% +, 90% Metastasis
J7 97 F 49 Lymph node Metastatic carcinoma from breast – – – – – +++, 100% Metastasis
J8 98 F 78 Lymph node Metastatic carcinoma from breast – – – – +, 45% – Metastasis
J9 99 F 39 Lymph node Metastatic carcinoma from breast – – – – +, 30% – Metastasis
J10 100 F 45 Lymph node Metastatic carcinoma from breast – – – ++, 99% – +, 100% Metastasis
– – M 58 Skin Malignant melanoma (tissue marker) – Malignant

† For precise diagnosis, refer to pathology description.

**The grade 1-3 (or I-III) in Pathology Diagnosis is equivalent to well-differentiated, moderately-differentiated or poorly differentiated, respectively, under microscope.
Grade 1 or well-differentiated: Cells appear normal and are not growing rapidly.
Grade 2 or moderately-differentiated: Cells appear slightly different than normal.
Grade 3 or poorly differentiated: Cells appear abnormal and tend to grow and spread more aggressively.
Grade 4 or undifferentiated: *(for certain tumors), features are not significantly distinguishing to make it look any different from undifferentiated cancers which occur in other organs.

Staining Scoring: "-" - no staining; "+-" - borderline staining; "+" - weak staining; "++" - moderate staining; "+++" - strong staining; "%" - percentage of positive cells.

TNM grading:

T - Primary tumor
Tx - Primary tumor cannot be assessed
T0 - No evidence of primary tumor
Tis - Carcinoma in situ; intraepithelial or invasion of lamina propria
T1 - Tumor invades submucosa
T2 - Tumor invades muscularis propria
T3 - Tumor invades through muscularis propria into subserosa or into non-peritonealized pericolic or perirectal tissues.
T4 - Tumor directly invades other organs or structures and/or perforate visceral peritoneum

N - Regional lymph nodes
Nx - Regional lymph nodes cannot be assessed
N0 - No regional lymph node metastasis
N1 - Metastasis in 1 to 3 regional lymph nodes
N2 - Metastasis in 4 or more regional lymph nodes

M - Distant metastasis
Mx - Distant metastasis cannot be assessed
M0 - No distant metastasis
M1 - Distant metastasis

Find overlapping cases with this tissue array:
© 2003 - 2011 US Biomax Inc., custsrv@biomax.us, Tel: (800) 935-1357 | Privacy Policy

Authorize.Net Seal Starfield Seal